Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization, MV -95% Improvement Relative Risk Hospitalization, PSM -105% Hospitalization, delta -100% Hospitalization, omicron -111% c19early.org/r Gershengorn et al. Casirivimab/i.. for COVID-19 EARLY Favors casirivimab/im.. Favors control
The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants
Gershengorn et al., PLOS ONE, doi:10.1371/journal.pone.0278770
Gershengorn et al., The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants, PLOS ONE, doi:10.1371/journal.pone.0278770
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 2,083 outpatients in the USA, showing higher risk of hospitalization with casirivimab/imdevimab, without statistical significance. There may be significant unadjusted confounding by indication.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan]. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication possible.
risk of hospitalization, 95.0% higher, OR 1.95, p = 0.09, treatment 369, control 5,915, adjusted per study, multivariable, day 30, RR approximated with OR.
risk of hospitalization, 104.9% higher, RR 2.05, p = 0.009, treatment 21 of 369 (5.7%), control 41 of 1,476 (2.8%), propensity score matching, day 30, Figure 2, PSM cohort.
risk of hospitalization, 100% higher, RR 2.00, p = 0.07, treatment 11 of 213 (5.2%), control 22 of 852 (2.6%), delta, propensity score matching, day 30, Figure 2, PSM cohort.
risk of hospitalization, 110.5% higher, RR 2.11, p = 0.06, treatment 10 of 156 (6.4%), control 19 of 624 (3.0%), omicron, propensity score matching, day 30, Figure 2, PSM cohort.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gershengorn et al., 2 Dec 2022, retrospective, USA, peer-reviewed, 6 authors.
Contact: hbg20@med.miami.edu, hsro@miami.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Abstract: PLOS ONE RESEARCH ARTICLE The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants Hayley B. Gershengorn ID1,2*, Samira Patel3, Tanira Ferreira1, Sankalp Das3, Dipen J. Parekh4, Bhavarth Shukla5 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 1 Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, United States of America, 2 Division of Critical Care Medicine, Albert Einstein College of Medicine, Bronx, NY, United States of America, 3 Care Transformation, University of Miami Hospital and Clinics, Miami, FL, United States of America, 4 Department of Urology, University of Miami Miller School of Medicine, Miami, FL, United States of America, 5 Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, United States of America * hbg20@med.miami.edu Abstract OPEN ACCESS Background Citation: Gershengorn HB, Patel S, Ferreira T, Das S, Parekh DJ, Shukla B (2022) The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants. PLoS ONE 17(12): e0278770. https://doi.org/10.1371/ journal.pone.0278770 In vitro studies suggesting that REGEN-COV (casirivimab plus imdevimab monoclonal antibodies) had poor efficacy against Omicron-variant SARS-CoV-2 infection led to amendment of REGEN-COV’s Emergency Use Authorization to recommend use only in regions without high Omicron prevalence. REGEN-COV’s relative clinical effectiveness for Omicron is unknown. Editor: Vipa Thanachartwet, Mahidol University, Faculty of Tropical Medicine, THAILAND Methods and findings Received: July 26, 2022 Accepted: November 23, 2022 Published: December 2, 2022 Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0278770 Copyright: © 2022 Gershengorn et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: Data cannot be shared publicly because of HIPAA. Data are available from the University of Miami Institutional Data Access / Ethics Committee (contact via We conducted a retrospective cohort study of non-hospitalized adults who tested positive for SARS-CoV-2 by polymerase chain reaction at the University of Miami Health System from July 19 –November 21, 2021 (Delta period) and December 6, 2021 –January 7, 2022 (Omicron period). Subjects were stratified be REGEN-COV receipt within 72h of test positivity and by time period of infection. We constructed multivariable logistic regression models to assess the differential association of REGEN-COV receipt with hospitalization within 30 days (primary outcome) and ED presentation; all models included three exposure terms (REGEN-COV receipt, Omicron vs Delta period, interaction of REGEN-COV with time period) and potential confounders (vaccination status, vaccine boosting, cancer diagnosis). Our cohort consisted of 2,083 adults in the Delta period (213 [10.2%] received REGENCOV) and 4,201 in the Omicron period (156 [3.7%]..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit